Get started

PFE

💉 Pfizer, Inc. Goes Bearish | 44, 39 and 34 Coming NextThe PFE stock, Pfizer, Inc., looks like is about to take a deep dive... Going red... Let's have a look! The most obvious signal is the weekly candle today moving below EMA50, telling us that this stock is preparing to drop for months. Pfizer, Inc. peaked December 2021. In mid-December 2022 PFE printed the inverted hammer bearish candlestick pattern or shooting star. This candlestick came at a long-term lower high (Dec. 2022 vs Dec. 2021). Trading volume has been decreasing since November 2020. The RSI has moved below 50, now bearish, and is trending down strong. The next and at the same time critical support level is 48.24. If this level breaks, PFE is going to move to 39.91 as a new low with even lower possible, but this level is the main one. Bearish target of 39.91 at 0.618 Fib. retracement level followed by 0.786 or 33.98. There is something going on at Twitter as well... I don't know... Do your own research... Not only about trading but also about your health. Thank you for reading. Namaste.
NYSE:PFEShort
by MasterAnanda
1
3/30 Watchlist + Notes SPY - Interesting day on SPY. We said yesterday that the markets could realistically go either way, but we were watching more so to the downside due to the failed 2U formed on Monday that was followed by a 2D yesterday, and having that small bearish bias by simply playing what is in front of us vs using other reasons for bias. SPY ended up gapping up premarket and closing green on the day with little to no upside wick. Based on today's movement, I believe that we will see some continuation to the upside tomorrow. With that being said, we still have the gap created in premarket to fill. I think that we will test last weeks high at 402.49 either tomorrow or Friday, but I do think that it will happen at some point sooner rather than later. I am open to playing both sides tomorrow, but it will depend on whether we break today's high and test last weeks high, or if we break today's low and try to fill that gap to the downside. It is worth noting also that we are sitting on the weekly upper trendline Final thoughts: I am forced to have a bullish bias for tomorrow, which I believe to be about 75% valid. I still think there is a chance we fill that downside gap before pushing higher Watchlist + Bias: AMD - 2-1 Daily: Neutral COST - 2-1 Daily: Neutral PFE - 2-1 Daily: Slightly Bullish GOOG - 2-1 Daily: Neutral NFLX - 2-1 Daily: Bullish JNJ - 2-1 Daily: Slightly Bullish FDX - 3-1-2U Weekly: Bullish - Today we broke out of the 3-1 weekly setup to the upside. Looking to target 226.06 Main Watch: JNJ and GOOG JNJ - Weekly chart is indicating we have hit a low and are looking to reverse to the upside soon. Going into tomorrow, I am hoping to see us continue up to the 154.13 level before hopefully taking out 154.54 GOOG - GOOG has room to both sides. There is a large FVG on both sides as well that relate to my targets for each side. To the downside, we have a daily FVG at yesterdays low of 100.28. To the upside we have a FVG starting at yesterdays high of 103.00, and I also have a target at the 50% retrace of that upside FVG at 103.87. Both of these targets are easily attainable in my opinion for tomorrow depending on which side we break out to. I don't have a bias as to which side id rather play, but I think that it will more so depend on how the markets are moving as a whole tomorrow. Remember, with these 2-1 setups, we are looking to play WITH momentum and not fight it. Yesterday's Main Watch: MRNA: (Status:) Loser (Personally Trade?) No MRNA broke yesterdays high within the first 5 minutes of market open, which is not what we were looking for. We were looking to play downside only, and because of this movement, we did not enter. It is worth noting that both times MRNA broke yesterdays high, it was almost immediately shot back down, which shows that we would have gotten smoked if we tried playing upside. This is a good example of why we look at longer time frames like the weekly and monthly to develop a bias, and then stick to that bias. Watchlist Stats For The Week: 2/3 on SPY predictions 2/3 on Main Watch Plays Top Winner: NVDA (75%+) Personal Stats: 4/6 For The Week: Overall Green/Red?: Green (Day and Week)
AMEX:SPY
by Alanger17
Pfizer Stock: More Than Just COVID-19 VaccinesYou may be familiar with the negative sentiment surrounding Pfizer, with many citing the company's heavy reliance on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid as a cause for concern. In addition to this, several of Pfizer's top-selling drugs will face patent expirations in the near future, leading many to believe that the company's stock will suffer. While there are certainly challenges facing Pfizer, the conclusion that its stock will suffer is flawed. Despite the company's current predicament, there is a lot to be excited about. Let's explore why Pfizer's stock is becoming increasingly attractive. Over the past five weeks, Pfizer has received a string of positive news. The U.S. Food and Drug Administration (FDA) approved Cibinqo for the treatment of adolescents with atopic dermatitis, marking a significant milestone for the company's growth strategy. Additionally, a late-stage study evaluating the combination of Talzenna and Xtandi to treat metastatic castration-resistant prostate cancer produced positive results, reducing the risk of disease progression or death by 37%. Furthermore, Pfizer announced that regulatory applications for elranatamab had been accepted by the FDA and the European Medicines Agency for the treatment of multiple myeloma. The company expects FDA approval to be granted later this year. In addition, an FDA advisory committee voted to approve Pfizer's respiratory syncytial virus (RSV) vaccine for older adults, which could open up a major market opportunity for the company. On March 10, the FDA approved Zavzpret for the treatment of migraine. Pfizer acquired the drug as part of its purchase of Biohaven in 2022. The company also announced plans to acquire Seagen for $43 billion, which caused Pfizer's stock to rise significantly. The acquisition will provide Pfizer with four approved cancer drugs and promising antibody-drug conjugates (ADCs) that could generate $10 billion in risk-adjusted revenue by 2030. Despite all of these positive developments, Pfizer's stock remains undervalued by investors. Its price is still nearly 35% below its late 2021 high, trading at just 12 times expected earnings. However, the company's dividend has risen to 4.1%, its highest level since mid-2021. Investors seem to be fixated on the difficulties associated with COVID-19 and its treatment, but Pfizer predicts that even on this front, there is good news to come. The company expects demand for Comirnaty to rise to 98 million doses by 2026 due to the launch of the combination flu vaccine COVID. Additionally, demand for Paxlovid is predicted to grow steadily over the next few years, with the possibility of promoting antiviral therapy in China. In conclusion, while there are certainly challenges facing Pfizer, the outlook for the company's stock is better than many people think. Despite the conventional wisdom that Pfizer's stock will suffer, the company is making significant strides towards achieving its goals. Investors should take note of the recent positive developments and consider investing in this pharmaceutical giant.
NYSE:PFEShort
by FOREXN1
8
PFIZER (PFE) 6M Trading Analisys (TA)6M Chart, PFE , on February 6, 2023, the signals on MACD have been steadily moving NE, after piercing below the histogram on July 2012; On July 2021, reached its ATH (All Time High); The RSI signal bounced over 70 and is now facing SE to test the line of 50, after bouncing up from it on January 2020; The price has been steadily falling since the ATH, from $60 to $43, heading down to test the 100 days MA signal, at this moment there is a probability for the price to bounce up before continuing its way down to test the 100 MA signal, which is the optimistic approach, but remember "In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten. I've found that when the market's going down and you buy funds wisely, at some point in the future you will be happy. You won't get there by reading: "Now is the time to buy". Today this ticker has a Volume of 5.297M with a Market Cap of 246B. This Company PAYS DIVIDENDS TO SHAREHOLDERS Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY. Good Luck! Gráfico de 6M, ( PFE ), al 6 de febrero de 2023, las señales en MACD se han estado moviendo constantemente hacia el NE, luego de cruzarse por debajo del histograma en julio de 2012; En julio de 2021, alcanzó su ATH (Mayor Precio Histórico); La señal RSI rebotó sobre 70 y ahora se dirige al SE para probar la señal de 50, luego de rebotar ahi en enero de 2020; El precio ha estado cayendo constantemente desde el ATH, de $60 a $43, bajando para probar la señal de 100 días MA, en este momento existe la probabilidad de que el precio rebote antes de continuar su camino hacia abajo para probar la señal de 100 MA, que es el enfoque optimista, pero recuerda: "En este negocio, si eres bueno, tienes razón seis de cada diez veces. Nunca vas a tener razón nueve de cada diez veces. Descubrí que cuando el mercado está cayendo y compras fondos sabiamente, en algún momento en el futuro serás feliz. No llegarás allí leyendo: "Ahora es el momento de comprar". Hoy este ticker tiene un Volumen de 5.297M con una Capitalización de Mercado de 246B. Esta Empresa PAGA DIVIDENDOS A LOS ACCIONISTAS Pfizer Inc. es una compañía biofarmacéutica global basada en la investigación. Se dedica al descubrimiento, desarrollo, fabricación, comercialización, venta y distribución de productos biofarmacéuticos en todo el mundo. La firma trabaja en mercados desarrollados y emergentes para promover el bienestar, la prevención, los tratamientos y las curas que desafían las enfermedades más temidas. La empresa fue fundada por Charles Pfizer Sr. y Charles Erhart en 1849 y tiene su sede en Nueva York, NY. ¡Buena suerte! “I believe in analysis and not forecasting.” / "Creo en el análisis y no en el pronóstico". REMEMBER : I am not a financial adviser nor is any content in this article presented as financial advice. The information provided in this blog post and any other posts that I make, and any accompanying material is for informational purposes only. It should not be considered financial or investment advice of any kind. One should consult with a financial or investment professional to determine what may be best for your individual needs. RECUERDE : No soy un asesor financiero y el contenido de este artículo no se presenta como asesoramiento financiero. La información provista en esta publicación de blog y cualquier otra publicación que haga y cualquier material que la acompaña es solo para fines informativos. No debe considerarse asesoramiento financiero o de inversión de ningún tipo. Se debe consultar con un profesional financiero o de inversiones para determinar qué es lo mejor para sus necesidades individuales.
NYSE:PFELong
by rodulfox
$PFE: Interesting juncture here...Pfizer has a curious setup where both an uptrend or down trend could trigger next, depending on which extreme of last week's range is crossed first. As per the chart, you can go long on a break of last week's high or short on a break of last week's low, with stops as depicted on chart. Targets may be subject to updates, if price action forms larger consolidation patterns in the direction of the trade and the initial entry isn't stopped. Odds of the trade working and making some progress in the next week are big if the trade is triggered, you could secure some gains by Friday close, if the target or the stop aren't hit, or just exit the trade altogether to revisit it next week, if continuation occurs. Best of luck! Ivan Labrie.
NYSE:PFE
by IvanLabrie
1
Potential 2-1-2 daily setupsPFE - failed 2u-1 on the daily, looking for more downside tomorrow. Put Trigger below 44.83. Put SL/Call trigger set at 45.32 JNJ - has a 2-1- on the daily. Feeling neutral but would prefer downside on this play. Call trigger above 169.62, Put trigger below 167.50. JNJ has earnings report tomorrow so be careful trading this one. (SL for call and put trigger is the other trigger) HTHT - failed 2u-1 on the daily. Big gap to the downside on the daily. Only looking at puts below 48.06. SL above 48.95
NYSE:PFE
by Alanger17
Pfizer in a bull flag.Pfizer - 30d expiry - We look to Buy a break of 48.31 (stop at 46.56) Short term bias has turned positive. Posted a bullish Flag formation. A break of 48.26 is needed to confirm the outlook. A break of the recent high at 48.26 should result in a further move higher. Short term momentum is bullish. This stock has seen good sales growth. The bias is to break to the upside. Our profit targets will be 52.69 and 53.69 Resistance: 48.00 / 49.70 / 52.00 Support: 46.70 / 46.00 / 44.70 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFELong
by Saxo
1
PFE (Range Trade)Since the recent news relative to the authorization this past week, price has been making higher highs and lower lows. Only 6 times this year price played around in the $54 -$56 area. I'm banking on price exhaustion from the recent "good" news this past week. Daily is overbought as well. Maybe we can get a bar close or two this week lower than previous to give us some time. If price reaches this resistance area, we will reassess Might wait til the fed decision and cpi reports pass next week to get a second look.
NYSE:PFEShort
by Redimere_91
PFIZER Broke above its 2022 Bear Channel!Pfizer (PFE) broke and closed today above the Channel Down that has been dominating the 2022 Bear Market since the January 11 High. At the same time the 1D RSI has been ranging and while the 1D MA200 (orange trend-line) held successfully last time, we do expect one last test or for an even more comfortable long-term buy, the 1D MA50 (blue trend-line). As you may notice, the Fibonacci retracement levels since the All Time High, formed solid Resistance and Support levels during the downtrend, so after the next pull-back our target will by the 0.786 Fib at 57.35. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:PFE
by TradingShot
2
PFE, 10d+/13.88%rsing cycle 13.88% more than 10 days. ================================================================================================================================================================== This data is analyzed by robots. Analyze historical trends based on The Adam Theory of Markets (20 moving averages/60 moving averages/120 moving averages/240 moving averages) and estimate the trend in the next 10 days. The white line is the robot's expected price, and the upper and lower horizontal line stop loss and stop profit prices have no financial basis. The results are for reference only.
NYSE:PFELong
by Tonyder
Pfeizer to Set New Local Lows. PFEAnother zigzag well in formation with a triangular B Wave. We are anticipating C Wave Shortly. Do not be dissuaded by diminshing negative momentum - Elliott prevails over all. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:PFEShort
by Rykin_Capital
Pfeizer is going down. PFEThese guys apparently manufacture COVID vaccines that do not seem to work. Anyway, this one is heading low. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:PFEShort
by Rykin_Capital
Longing Pfeizer on the Rebound. PFEPost a very juicy short on PFE, its time to reverse the direction. When facts change, our opinion also changes. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:PFELong
by Rykin_Capital
Accumulating PFE from $46.00 - $47.50 This is one of the stocks I hold indefinitely for dividends. we're at the bottom of our current channel and a double bottom is forming in a major area of support. In my previous post I stated my accumulation sections are in the lower end of the channel, so this is prime real estate to enter. Momentum downwards has come to a halt and I believe we will retest the center channel line from this point. I am diversifying a portion of profits I made from the last 2 trade set ups I've posted into PFE. A fundamentally sound entity in our current market economy. I'm sure you could assume why.
NYSE:PFELong
by WatsonsView